CD38-Targeted ImmunoPET

A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma

What's the purpose of the trial?

89Zr-DFO-daratumumab is a novel immunoPET tracer, designed to detect CD38 on myeloma cells and allow visualization of myeloma in a PET scanner. A phase I study of 89Zr-DFO-daratumumab demonstrated safety and successful visualization of myeloma with 89Zr-DFO-daratumumab. This will be a phase II study of 89Zr-DFO-daratumumab to evaluate potential clinical applications of this novel imaging agent.

Trial status

Accepting patients

Phase
Phase 2
Enrollment
60
Last Updated
10 months ago

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

89Zr-daratumumab PET/CT

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.